[1]
Moss, MD, R.B., Carleton, PhD, F., Lollo, PhD, C.P. and Carlo, PhD, D.J. 2020. An open-label, randomized, single-dose, two-period, two-treatment crossover bioavailability study comparing 5 mg/0.5 mL of intramuscular naloxone hydrochloride to 2 mg/0.4 mL intramuscular naloxone hydrochloride autoinjector in healthy subjects. Journal of Opioid Management. 16, 3 (May 2020), 209–214. DOI:https://doi.org/10.5055/jom.2020.0569.